title: The clinical use of porcine factor VIII.
abstract: Extensive worldwide experience with PE-fractionated porcine factor VIII concentrate has confirmed the expectation that the produce has an important place in the management of hemophiliacs with inhibitors, and that the problems which constrained the use of the original animal factor VIII concentrates have been largely overcome. A particular advantage, compared with PCCs and derivatives, is that dosage and effects can be monitored with conventional coagulation tests.
authors.affiliation: Royal Free Hospital, London, England.
authors.forename: P B
authors.initials: PB
authors.lastname: Kernoff
mesh_terms: D000818:Animals; D005169:Factor VIII / Q000008:administration & dosage / Q000266:history / Q000627:therapeutic use*; D006467:Hemophilia A / Q000188:drug therapy*; D049673:History, 20th Century; D006801:Humans; D013552:Swine
chemical_list: D005169:Factor VIII